Nuo Therapeutics(OTC) AURX

Nuo Therapeutics helps treat hard-to-heal wounds using a patient’s own blood. Its main product, Aurix, creates a gel from blood to support healing. Hospitals and clinics use this for patients with chronic wounds, like diabetic ulcers.

Products and Services

• Aurix System (100% of product revenue): Device that turns a patient’s blood into a healing gel for chronic wounds, used mainly in U.S. wound care clinics.
• Private Label Aurix: Aurix sold under the Smith+Nephew brand, distributed exclusively in the U.S. through a partnership.
• Wound Dressing Kit: Supplies for applying the Aurix gel to wounds, included with each treatment.
• Reagent Kit: Contains chemicals needed to make the gel, with some reagents historically sourced from single suppliers and others now from dual sources.
• Centrifuge Device: Machine that separates blood components at the point of care, sold to clinics and Smith+Nephew.

Growth and Expansion

• Restarted commercial operations in October 2021 after gaining Medicare coverage for Aurix.
• Signed a five-year exclusive U.S. distribution deal with Smith+Nephew in March 2025.
• Launched private label Aurix with Smith+Nephew in October 2025.
• Expanded sales agent network to over 200 representatives by December 2025.
• No major acquisitions or international expansion reported as of 2025.

What Makes Nuo Therapeutics Stand Out

Nuo Therapeutics focuses on a single, FDA-cleared product with Medicare coverage, making it accessible for U.S. clinics. Its exclusive partnership with Smith+Nephew broadens reach without large internal sales teams. The company’s point-of-care approach allows immediate treatment using a patient’s own blood, reducing wait times for wound care.

Five Things You Need to Know

• Product revenue was $3.1 million in 2025, up 126% from 2024.
• Gross margin fell to 67% in 2025, down from 78% in 2024.
• Net loss was $2.5 million in 2025, slightly higher than 2024.
• Customer A made up 23% of 2025 revenue; no other customer exceeded 10%.
• Cash at year-end 2025 was $548,946, with ongoing funding needs noted.

Bottom Line

Nuo Therapeutics has rebuilt its business around a single wound care product and a key distribution partnership. The company’s growth depends on expanding its U.S. presence and managing operational risks.